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Secondary malignancies are observed more frerquently after HSCT compared with the general population.1 Use of newer therapies and supr
portive care has improved the number of survivors exr
periencing more late effects secondary to graftrversusr
host disease (GVHD) and autoimmunity. Exposure 
to chemoradiation before and during transplant along 
with the occurrence of GVHD carries the highest risk 
for developing secondary malignancies.2 Although the 
majority are hematological malignancies like leukemias 
and lymphomas, other malignancies involving the oral 
cavity, skin, and gut are not uncommon. Squamous cell 
carcinoma (SCC) is the most common form of solid tur
mors originating in different sites. A large, international 
casercontrol study showed that the strongest risk facr
tors for SCC were the severity of chronic GVHD and 
the duration of immunosuppressive therapy.3 We presr
ent two cases of SCC affecting the lower lip diagnosed 
several years after allogeneic HSCT. Both patients had 
extensive chronic GVHD. 
CASE 1
A 25ryearrold male diagnosed with chronic myelogr
enous leukemia (CML) in May 1995 underwent alr
logeneic HSCT from a fully human leucocyte antigen 
(HLA)rmatched sibling five months after diagnosis. He 
received busulphan and cyclophosphamide for condir
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allogeneic hemopoietic stem cell transplantation (hsct) has been considered a curative treatment op-
tion for many hematological and non-hematological disorders. despite the use of advanced methods of 
tissue typing and new therapies, graft versus host disease (GVhd) remains a major obstacle. secondary 
malignancies are also among the most serious long-term complications after hsct including leukemia, 
lymphomas, and to a lesser extent, solid tumors. the most commonly observed solid tumor is squamous 
cell carcinoma (scc). We report two cases of scc of the lower lip diagnosed several years after hsct. 
both cases were complicated with GVhd prior to the development of scc and had a successful outcome 
with minimal surgical intervention.
tioning. Shortrcourse methotrexate and cyclosporine A 
(CSA) were used for GVHD prophylaxis. There were 
no signs of GVHD by day 120 and CSA was tapered 
over the following three months. Ten months after the 
transplant, he had lichenoid lesions in the oral mucosa, 
which were diagnosed with mucosal biopsy as chronic 
GVHD. He was treated with CSA and prednisone. 
Immune suppression was tapered gradually and disconr
tinued after several months.
Thirtyrthree months posttransplantation he had an 
exacerbation of GVHD. CSA and prednisone were rer
sumed and mycophenolate mofetil (MMF) 2 g daily in 
two divided doses was added. Fortyrtwo months after 
transplantation, MMF was replaced with tacrolimus 
due to poor control of GVHD. Two months later, he 
presented with a nodule in the right lower lip, measuring 
1.5×1.5 cm, and skinrcolored with a verrucous surface. 
Biopsy showed grade I squamous cell carcinoma (SCC), 
1 cm wide and 0.2 cm deep without invasion of vessels 
or muscles (Figure 1ard) that was treated by wide local 
excision. Tacrolimus was continued for another 3 years 
for GVHD control. Followrup after 10 years showed 
no relapse or development of new lesions.
CASE 2
A 42ryearrold man diagnosed with multiple myelor
ma was treated with melphalan and prednisone over 
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Figure 1a. Biopsy from lower lip lesion in a 25-year-old male 
with cgVHd after allogeneic stem cell transplant for chronic 
myelogenous leukemia.
Figure 1b.  Biopsy from lower lip lesion in a 25-year-old male 
with chronic graft-versus-host disease after allogeneic stem cell 
transplant for chronic myelogenous leukemia.
Figure 1c. Biopsy from lower lip lesion in a 25-year-old male with 
chronic graft-versus-host disease after allogeneic stem cell 
transplant for chronic myelogenous leukemia.
Figure 1d. Biopsy from lower lip lesion in a 25-year-old male with 
chronic graft-versus-host disease after allogeneic stem cell 
transplant for chronic myelogenous leukemia.
6 months. Subsequently, he underwent allogeneic 
HSCT stem cell from a full HLArmatched sibling 
donor using cyclophosphamide and total body irradiar
tion (TBI) for conditioning. As GVHD prophylaxis, 
he received shortrcourse methotrexate and cyclospor
rine. He developed acute GVHD of the skin and gut 
after three months. He was treated with methylpredr
nisone and CSA. About five months after transplant, 
he had lichenoid lesions on the oral mucosa and generr
alized sclerodermarlike changes in the skin. Skin and 
oral biopsies confirmed the diagnosis chronic GVHD. 
He was treated with CSA and prednisone. Additional 
GVHD treatments including MMF and sirolimus 
were required to control GVHD exacerbations at difr
ferent time points and he remained on immunosupr
pressive therapy 10 years after transplantation. Ten 
years post transplant he developed a 4×3 cm colored 
skin nodule on the lower lip (Figure 2). The diagnosis 
of SCC was confirmed by biopsy (Figure 3). The ler
sion was surgically removed by elliptical excision. 
DISCUSSION
HSCT is a known risk factor for SCC. We reviewed 
the literature for SCC involving the lips after SCT 
(Table 2). Hasegawa et al4 reported 31 patients who 
developed secondary malignancies out of 557 patients 
who underwent HSCT. Of these 31 patients, 7 had 
SCC of the oral cavity. Two patients had acute myeloid 
leukemia (AML), one had nonrHodgkin lymphoma 
(NHL), three patients had aplastic anemia (AA) and 
one patient had multiple myeloma (MM). Six had 
acute GVHD and all had chronic GVHD and out of 
seven, six were males. They developed secondary canr
cers at the average of 8.8 years from the transplant date 
with an average follow up of 1.33 years after secondary 
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Figure 2. Squamous 
cell carcinoma of 
the lower lip in a 
42-year-old man with 
oral mucosal graft-
versus-host disease 
after allogeneic stem 
cell transplant for 
multiple myeloma.
Figure 3a. Biopsy of 
the lower lip lesion 
showing squamous 
cell carcinoma in a 
42-year-old man with 
oral mucosal graft-
versus-host disease 
after allogeneic stem 
cell transplant for 
multiple myeloma.
Table 1. Characteristics of the two cases.
 Case 1 Case 2
   diagnosis CMl MM
   age at diagnosis (years) 25 42
   Sex Male Male
   risk factors none none
   age at SCT (years) 25 42
   Conditioning protocol Cyclophosphamide and busulphan
Cyclophosphamide 
and TBi
   gVHd prophylaxis Cyclosporine and methotrexate
Cyclosporine and 
methotrexate
   gVHd sites Oral Oral, skin and gut
   location of squamous cell 
   carcinoma lower lip lower lip
   interval between SCT and 
   SCC 44 months 10 years
   Treatment Surgery Surgery
   Follow up 10 years, no relapse died after 2 years
CMl: chronic myelogenous leukemia, MM: multiple myeloma, TBi: total body irradiation, gVHd: graft-versus-host 
disease, SCC: squamous cell carcinoma
malignancies. Three of them died while the other four 
were still alive at the time of reporting.
Lishner et al2 also reported a 34ryearrold male with 
hepatitis B virus and aplastic anemia who had SCT 
after conditioning with cyclophosphamide and TBI. 
He then developed GVHD, which was treated with 
prednisone and azathioprine. Five years later, he der
veloped a shallow ulcer on the lower lip. One year later 
it became a tumor with a large ulcer extending to the 
right buccal and vestibular mucosa and adjacent ginr
giva. The patient underwent radical surgical resection 
and reconstruction of the jaw, but died later because 
of severe infections. Bhatia et al1 also reported six par
tients with SCC of the oral cavity, out of 2129 patients 
who underwent HSCT due to hematological maligr
nancies. The specific location was not mentioned, but 
three of them were raised from salivary glands. The 
median age at transplant was 25.7 years; 5 were male 
and SCC developed 4.7 to 11.7 years after SCT. They 
all had GVHD. Witherspoon et al3 reported two cases 
of oral cavity SCC, among 2246 patients who underr
went HSCT and had acute GVHD.
Jansisyanont et al7 reported a woman with SCC 
of the dorsum of the tongue 15 years after SCT for 
Fanconi anemia. The tumor was partially resected, 
but recurred six months after surgery. Millen et al8 rer
ported a case of SCC in the buccal mucosa nine years 
after SCT for Fanconi anemia. The patient received 
GVHD prophylaxis with lowrdose cyclophosphamide 
and TBI with oropharyngeal shielding, and developed 
acute GVHD of the skin and gut followed by chronic 
cutaneous and hepatic GVHD. The tumor was surgir
cally resected but recurred in the right parotid gland 
one month later, which was treated with radiotherapy. 
He died three months postroperatively.
Zhang et al9 reported three cases of oral cavity 
SCC. The first was a case of SCC of the tongue eight 
years postrtransplant for CML. He developed GVHD 
one year after transplant, involving the skin, gastroinr
testinal tract and oral mucosa. He was treated with 
topical steroids. The patient underwent hemiglosr
sectomy, bilateral neck dissection and postroperative 
radiotherapy. There was no recurrence two years after 
treatment. The patient had a history of occasional alr
cohol drinking but no history of smoking. The second 
case was carcinoma in situ (CIS) of the lower labial 
mucosa seven years after SCT for CML. He developed 
oral GVHD and was treated with topical corticoster
roids. The tumor was totally excised with no further 
follow up reported. The patient had a history of heavy 
smoking. The third case was CIS of the lower lip five 
years after SCT for AML. Three months after transr
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Table 3. reported cases of squamous cell carcinoma of the lower lip.
 Lishner et al, 1990
Zhang 
et al, 2002
Zhang 
et al, 2002
   diagnosis aa CMl aMl
   age (years) 34 40 49
   Sex Male Male Male
   risk factors HBV Heavy smoking none
   age at SCT (years) 35 40 49 
   Conditioning protocol
Cyclophos-
phamide 
and TBi
TBi based TBi based
   gVHd prophylaxis not specified not specified not specified
   gVHd sites Oral cavity, skin, liver Oral cavity Oral cavity
   pathology
Moderate 
to poorly
differentiated
Carcinoma 
in situ
Carcinoma
in situ
   interval between SCT    
   and SCC (years) 6 7 5
   Treatment Surgery Surgical excision
Topical bleomycin, 
laser ablation, 
surgical excision
   Follow up died due to infection not reported
13 months, no 
recurrence
aa: aplastic anemia, CMl: chronic myelogenous leukemia, aMl: acute myeloid leukemia, HBV: hepatitis B virus, 
gVHd: graft-versus-host disease, TBi: total body irradiation.
plant, the patient developed mild oral GVHD and was 
treated with corticosteroid mouth rinse. The tumor was 
surgically excised with a wide margin and there was no 
recurrence 13 months after excision. The patient had no 
history of smoking or alcohol consumption. Abdelsayed 
et al6 reported a male patient who developed CIS of 
buccal mucosa two years after SCT and GVHD. The 
total number of reported cases of SCC involving the 
oral mucosa is ten, with three in the lower lip (Table 3). 
The reported cases of SCC after SCT mostly developed 
in male patients, as in our reported cases. Most of them 
had chronic GVHD involving the skin and the oral mur
cosa.The tumor developed after a mean of 5 years postr
transplant. In our two cases the tumor developed after 
4 and 10 years, respectively.
Although many aspects of the development of mar
lignant tumors are still incompletely understood, condir
tions have been identified under which malignancies der
velop at a higher frequency. These include, for example, 
actinic exposure of the skin and the mutagenic effect of 
ultraviolet light, genetic disorders that are associated 
with chromosome fragility, defect of repair enzymes, or 
cellular immune defects. A higher incidence of maligr
nancies has also been observed in patients receiving imr
munosuppressive therapy or after exposure to ionizing 
radiation.10,11 Certain viruses, such as EpsteinrBarr vir
rus, which is used in the laboratory to immortalize cell 
lines, can transform cells in vivo, which then may show 
uncontrolled growth and evolve into malignacies.12
We conclude that GVHD might be a risk factor for 
SCC of the oral mucosa, which apparently occurs more 
often in male patients who have undergone HSCT 
earlier in life. However, further study and a review of a 
larger cohort of patients in a large registry is required to 
confirm this conclusion.
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